{
    "Rank": 1031,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT04173325",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "GCC-20-009"
                },
                "Organization": {
                    "OrgFullName": "Augusta University",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer",
                "OfficialTitle": "Phase I Feasibility and Safety Study of Nivolumab in Combination With Irinotecan in Relapsed or Refractory Small Cell Lung Cancer (SCLC) Followed by Maintenance Nivolumab"
            },
            "StatusModule": {
                "StatusVerifiedDate": "June 2022",
                "OverallStatus": "Terminated",
                "WhyStopped": "Closed by the IRB 5/26/22 due to non-compliance",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "January 6, 2020",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "May 26, 2022",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "May 26, 2022",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "November 14, 2019",
                "StudyFirstSubmitQCDate": "November 20, 2019",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "November 21, 2019",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "June 10, 2022",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 14, 2022",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Nagla Abdel Karim",
                    "ResponsiblePartyInvestigatorTitle": "Professor, Hematology/Oncology, Director of Thoracic Oncology and Phase I Program",
                    "ResponsiblePartyInvestigatorAffiliation": "Augusta University"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Augusta University",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "Yes",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Small-cell Lung Cancer",
                        "Small Cell Lung Carcinoma"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Lung cancer",
                        "Relapsed lung cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "10",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Nivolumab and Irinotecan",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]",
                                    "Drug: Irinotecan Injection [Camptosar]"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]",
                            "InterventionDescription": "PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Nivolumab and Irinotecan"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Irinotecan Injection [Camptosar]",
                            "InterventionDescription": "Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Nivolumab and Irinotecan"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Evaluate the frequency and severity of adverse events in patients with small cell lung cancer after receiving nivolumab plus irinotecan followed by nivolumab maintenance.",
                            "PrimaryOutcomeDescription": "CTCAE v.4.0. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.",
                            "PrimaryOutcomeTimeFrame": "through study completion, an average of 1 year"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Overall response rate",
                            "SecondaryOutcomeDescription": "Tumor response evaluation with RECIST",
                            "SecondaryOutcomeTimeFrame": "through study completion, an average of 1 year"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Progression-free survival (PFS)",
                            "SecondaryOutcomeDescription": "PFS as measured from start of therapy till disease progression.",
                            "SecondaryOutcomeTimeFrame": "through study completion, an average of 1 year"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall survival (OS)",
                            "SecondaryOutcomeDescription": "OS as measured from start of therapy till date of death or last follow up assessment.",
                            "SecondaryOutcomeTimeFrame": "through study completion, an average of 1 year."
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nConfirmed SCLC with known UGT1A genotype.\nPatients who have received at least 1 prior platinum-based chemotherapy.\nLife expectancy of 3 months or more.\nMeasurable disease.\n\nExclusion Criteria:\n\nPatients with UGT1A polymorphism.\nCurrently receiving chemotherapy.\nPregnant and nursing women.",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Nagla A Karim, MD, PhD",
                            "OverallOfficialAffiliation": "Augusta University Georgia Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Georgia Cancer Center at AU Medical Center",
                            "LocationCity": "Augusta",
                            "LocationState": "Georgia",
                            "LocationZip": "30912",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000055752",
                            "ConditionMeshTerm": "Small Cell Lung Carcinoma"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000002283",
                            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
                        },
                        {
                            "ConditionAncestorId": "D000001984",
                            "ConditionAncestorTerm": "Bronchial Neoplasms"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M28013",
                            "ConditionBrowseLeafName": "Small Cell Lung Carcinoma",
                            "ConditionBrowseLeafAsFound": "Small Cell Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5230",
                            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4950",
                            "ConditionBrowseLeafName": "Bronchial Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T5271",
                            "ConditionBrowseLeafName": "Small Cell Lung Cancer",
                            "ConditionBrowseLeafAsFound": "Small Cell Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000077594",
                            "InterventionMeshTerm": "Nivolumab"
                        },
                        {
                            "InterventionMeshId": "D000077146",
                            "InterventionMeshTerm": "Irinotecan"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000074322",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000082082",
                            "InterventionAncestorTerm": "Immune Checkpoint Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000059004",
                            "InterventionAncestorTerm": "Topoisomerase I Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000059003",
                            "InterventionAncestorTerm": "Topoisomerase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M21550",
                            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M1854",
                            "InterventionBrowseLeafName": "Nivolumab",
                            "InterventionBrowseLeafAsFound": "Technique",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M1671",
                            "InterventionBrowseLeafName": "Irinotecan",
                            "InterventionBrowseLeafAsFound": "Conventional",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M1346",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2343",
                            "InterventionBrowseLeafName": "Immune Checkpoint Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M29039",
                            "InterventionBrowseLeafName": "Topoisomerase I Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "PhSol",
                            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        }
                    ]
                }
            }
        }
    }
}